References
- Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177–82
- Dybdal N, Leiberman G, Anderson S, McCune B, Bajamonde A, Cohen RL, et al. Determination of HER2 gene amplification by fluorescence in situ hybridization and concordance with the clinical trials immunohistochemical assay in women with metastatic breast cancer evaluated for treatment with trastuzumab. Breast Cancer Res Treat 2005; 93: 3–11
- Bartlett J, Mallon E, Cooke T. The clinical evaluation of HER-2 status: Which test to use?. J Pathol 2003; 199: 411–7
- Lal P, Salazar PA, Hudis CA, Ladanyi M, Chen B. HER-2 testing in breast cancer using immunohistochemical analysis and fluorescence in situ hybridization. Am J Clin Pathol 2004; 121: 631–6
- Hanna WM, Kwok K. Chromogenic in-situ hybridization: A viable alternative to fluorescence in-situ hybridization in the HER2 testing algorithm. Mod Pathol 2006; 19: 481–7
- Wolff AC, Hammond MEH, Schwartz JN, Hagerty K, Allred DC, et al. American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 testing in breast cancer. Arch Pathol Lab Med 2007; 131: 18–43
- Ellis IO, Bartlett J, Dowsett M, Humphreys S, Jasani B, Miller K, et al. Updated recommendations for HER2 testing in the UK. J Clin Pathol 2004; 57: 233–7
- Goldhirsch A, Glick JH, Gelber RD, Coates AS, Thürlimann B, Senn H-J, et al. International expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 2005; 16: 1569–83
- Dowsett M, Bartlett J, Ellis IO, Slater J, Hills M, Mallon E, et al. Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres. J Pathol 2003; 199: 418–23
- Hsi ED, Tubbs RR. Guidelines for HER2 testing in the UK. J Clin Pathol 2004; 57: 241–2
- Lewis F, Jackson P, Lane S, Coast G, Hanby AM. Testing for HER2 in breast cancer. Histopathology 2004; 45: 207–17
- Hammock L, Lewis M, Phillips C, Cohen C. Strong HER-2/neu protein overexpression by immunohistochemistry often does not predict oncogene amplification by fluorescence in situ hybridization. Hum Pathol 2003; 34: 1043–7